拉米夫定治疗深度黄疸HBeAg阴性慢性乙型肝炎的近期疗效分析

Clinic Analysis of Lamivudine Therapy in Deep Icteritious Patients with HBeAg Negative Chronic Hepatitis B Infection

目的探讨拉米夫定治疗深度黄疸HBeAg阴性慢性乙型肝炎的疗效及安全性。方法将230例深度黄疸HBeAg阴性慢性乙型肝炎随机分为治疗组(128例)和对照组(102例)。对照组给予综合治疗,治疗组在综合治疗的基础上加用拉米夫定抗病毒治疗,疗程6个月。结果治疗组血清总胆红素(TBil)、丙氨酸氨基转移酶(ALT)、球蛋白(Alb)和凝血酶原活动度(PTA)的改善优于对照组,乙肝病毒(HBV-DNA)定量亦明显下降,差异有统计学意义。治疗组仅9.38%发展成重症肝炎,明显低于对照组(35.29%)。结论拉米夫定治疗深度黄疸HBeAg阴性慢性乙型肝炎安全有效,且可阻止其进一步发展为慢性重症肝炎。

Objective To evaluate the effects and safety of lamivudine therapy in deep icteritious patients with HBeAg negative chronic hepatitis B infection. Methods 230 patients were randomly assigned in two groups. In group- Ⅰ, 102 patients received general treatment. In group-Ⅱ, 128 patients simultaneously received anti-HBV drug lamivudine and general therapy for 6 months. Results The levels of serum total bilirubin （TBIL）, alanine aminotransferase （ALT）, albumin （Alb）, and also the activity of prothrombin （PTA） in the samples of group-Ⅱ patients were restored. Furthermore, the level of serum HBV-DNA was significantly decreased. Only 9.38% of group-Ⅱ patients developed severe hepatitis （group-Ⅰ, 35.29% ）. Conclusion Lamivudine therapy is effective and safe in treating deep icteritious patients with HBeAg negative chronic hepatitis B infection.